Quebec-based Confab Laboratories has successfully undergone its second FDA audit for the manufacture and supply of pharmaceutical products to the U.S. The audit was a preapproval inspection for three drug products and demonstrated the company's conformity to cGMP. Confab's main focus is to provide manufacturing solutions for nonsterile conventional dosage forms with an efficient turnaround.
Confab’s chief executive officer, Guy Lamarre, commented, "The future looked bright, but this will be a key driver in sustaining our company’s growth in the long term." The company has increased the size of its facility by 20% in 2006 and is planning its next expansion to meet the needs of its clients and the industry. This year Confab has invested $5 million in its facilities.